Beijing Tong Ren Tang Chinese Medicine Co 3613.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

5.72

-1.04%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in HKD, from our data supplier.

FY2025

Revenue

HK$1.51bn

FY2016FY2025

Net income

HK$397.2m

FY2016FY2025

Free cash flow

HK$827.1m

FY2016FY2025

Shareholders' equity

HK$4.19bn

FY2016FY2025

Income statement

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	HK$1.51bn	HK$1.61bn	HK$1.52bn	HK$1.73bn	HK$1.56bn	HK$1.32bn	HK$1.43bn	HK$1.51bn	HK$1.27bn	HK$1.08bn
Gross profit	HK$925.6m	HK$1.07bn	HK$1.05bn	HK$1.15bn	HK$1.12bn	HK$952.9m	HK$1.01bn	HK$1.08bn	HK$916.4m	HK$795.1m
Research and development	HK$11.6m	HK$9.1m	HK$12.2m	HK$7.7m	HK$11.3m	HK$9.5m	HK$13.5m	HK$18.5m	HK$9.6m	HK$4.3m
Operating income	HK$472.2m	HK$576.9m	HK$624.1m	HK$811.6m	HK$778.5m	HK$669.4m	HK$652.0m	HK$698.0m	HK$597.7m	HK$527.5m
Net income	HK$397.2m	HK$500.3m	HK$540.4m	HK$645.9m	HK$607.8m	HK$542.5m	HK$556.1m	HK$580.7m	HK$490.0m	HK$420.3m
Diluted earnings per share	0.47	0.60	0.65	0.77	0.73	0.65	0.66	0.16	0.59	0.50

Balance sheet

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total assets	HK$4.66bn	HK$4.56bn	HK$4.43bn	HK$4.23bn	HK$3.83bn	HK$3.42bn	HK$3.14bn	HK$3.17bn	HK$2.76bn	HK$2.35bn
Cash and short-term investments	HK$2.28bn	HK$1.82bn	HK$2.38bn	HK$2.24bn	HK$2.28bn	HK$1.85bn	HK$1.97bn	HK$2.27bn	HK$1.90bn	HK$1.58bn
Total liabilities	HK$291.9m	HK$313.1m	HK$413.8m	HK$486.5m	HK$295.5m	HK$287.5m	HK$372.7m	HK$146.9m	HK$152.5m	HK$127.6m
Debt	HK$52.4m	HK$123.4m	HK$131.8m	HK$103.1m	HK$128.5m	HK$106.0m	HK$99.9m	HK$1.2m	HK$605,000	HK$556,000
Shareholders' equity	HK$4.19bn	HK$4.08bn	HK$3.87bn	HK$3.60bn	HK$3.42bn	HK$3.02bn	HK$2.66bn	HK$2.91bn	HK$2.49bn	HK$2.12bn
Shares outstanding	837m	837m	837m	837m	837m	837m	837m	3,630m	837m	837m

Cash flow

Fiscal years

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from operations	HK$868.2m	−HK$217.3m	HK$460.8m	HK$547.4m	HK$777.2m	HK$116.1m	HK$551.0m	HK$577.7m	HK$469.1m	HK$467.7m
Capital spending	−HK$41.2m	−HK$43.2m	−HK$21.9m	−HK$38.5m	−HK$23.4m	−HK$12.9m	−HK$17.0m	−HK$53.2m	−HK$34.1m	−HK$38.3m
Free cash flow	HK$827.1m	−HK$260.4m	HK$439.0m	HK$508.9m	HK$753.7m	HK$103.2m	HK$534.0m	HK$524.5m	HK$435.1m	HK$429.5m
Dividends paid	−HK$293.0m	−HK$276.2m	−HK$276.2m	−HK$443.7m	−HK$200.9m	−HK$192.5m	−HK$795.2m	−HK$159.0m	−HK$133.9m	−HK$108.8m

Latest quarters

By quarter end

	Jun 2026	Dec 2025	Sept 2025	Jun 2025	Mar 2025	Dec 2024	Sept 2024	Jun 2024
Revenue	HK$601.9m	HK$375.8m	HK$375.8m	HK$380.9m	HK$380.9m	HK$473.6m	HK$473.6m	HK$332.3m
Gross profit	HK$384.7m	HK$231.3m	HK$231.3m	HK$231.5m	HK$231.5m	HK$306.8m	HK$306.8m	HK$225.9m
Operating income	HK$218.8m	HK$103.4m	HK$103.4m	HK$132.7m	HK$132.7m	HK$159.0m	HK$159.0m	HK$129.4m
Net income	HK$198.2m	HK$81.2m	HK$81.2m	HK$117.4m	HK$117.4m	HK$140.2m	HK$140.2m	HK$109.9m
Diluted earnings per share	0.24	0.10	0.10	0.14	0.14	0.17	0.17	0.13
Cash from operations	HK$296.0m	HK$362.0m	HK$174.0m	HK$240.0m	HK$240.0m	HK$43.0m	HK$43.0m	−HK$151.0m
Capital spending	−HK$2.0m	−HK$24.0m	−HK$12.0m	−HK$8.0m	−HK$8.0m	−HK$15.0m	−HK$15.0m	−HK$5.0m
Free cash flow	HK$294.0m	HK$338.0m	HK$162.0m	HK$232.0m	HK$232.0m	HK$28.0m	HK$28.0m	−HK$156.0m
Total assets	HK$4.51bn	HK$4.66bn	HK$4.66bn	HK$4.53bn	HK$4.53bn	HK$4.56bn	HK$4.56bn	HK$4.28bn
Cash and short-term investments	HK$2.21bn	HK$2.28bn	HK$2.29bn	HK$2.01bn	HK$2.02bn	HK$1.83bn	HK$1.83bn	HK$1.79bn
Debt	HK$50.3m	HK$52.4m	HK$52.3m	HK$142.7m	HK$58.3m	HK$123.4m	HK$57.5m	HK$134.0m
Shareholders' equity	HK$4.05bn	HK$4.19bn	HK$4.19bn	HK$4.03bn	HK$4.03bn	HK$4.08bn	HK$4.08bn	HK$3.81bn

Financial ratios

Data as of 12 Oct 2026

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	61.2%	66.1%	68.7%	66.4%	71.9%	72.4%
Operating margin	31.5%	39.4%	45.7%	48.1%	50.3%	52.5%
Net margin	26.2%	31.0%	35.4%	37.3%	39.1%	41.2%
Return on equity	9.5%	12.3%	14.0%	17.9%	17.8%	18.0%
Return on assets	8.5%	11.0%	12.2%	15.3%	15.8%	15.9%
Free cash flow yield	19.4%	-3.7%	10.3%	12.5%	17.1%	2.8%
Revenue growth	-6.1%	5.7%	-11.9%	11.2%	18.3%	-8.2%
Earnings growth	-20.6%	-7.4%	-16.3%	6.3%	12.1%	-2.5%
Current ratio	19.65x	16.85x	11.65x	8.80x	15.38x	13.54x
Debt to equity	0.01x	0.01x	0.01x	0.01x	0.02x	0.00x
Equity ratio	89.9%	89.4%	87.2%	85.3%	89.1%	88.3%
Interest coverage	84.10x	97.85x	116.60x	178.54x	166.31x	160.71x
R&D as a share of sales	0.8%	0.6%	0.8%	0.4%	0.7%	0.7%
Buybacks as a share of market value	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Growth per year

Compound annual rate

	3 years	5 years	10 years
Revenue	-4.4%	2.8%	4.5%
Operating income	-16.5%	-6.7%	0.4%
Net income	-15.0%	-6.0%	1.2%

Average margins

Over each period

	1 year	3 years	5 years	10 years
Gross margin	63.7%	65.6%	67.7%	69.2%
Operating margin	33.6%	38.9%	42.5%	44.2%
Net margin	28.7%	32.7%	35.0%	36.3%

Valuation history

At each fiscal year end

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Price to earnings	17.9	14.7	18.8	14.8	18.5	12.6	17.7	77.0	18.1	20.9
Price to sales	4.7	4.6	6.7	5.5	7.2	5.2	6.9	29.5	7.0	8.1

Dividends and splits

Per share, in the currency the company pays

Paid for 12 years. Last went ex-dividend on 12 Jun 2026.

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Paid in the year	0.37	0.70	0.66	0.33	0.53	0.24	0.23	0.95

Sources and methodology

Data on this tab: Our data supplier
Chart on the Overview: TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.

Asset classes

Countries / Regions

Market tools

News & insights

Beijing Tong Ren Tang Chinese Medicine Co 3613.HK · HKD

Search any instrument

At a glance

Income statement

Balance sheet

Cash flow

Latest quarters

Financial ratios

Growth per year

Average margins

Valuation history

Dividends and splits

Sources and methodology